» Articles » PMID: 35156518

Ethanol Promoting the Upregulation of C-X-C Motif Chemokine Ligand 1(CXCL1) and C-X-C Motif Chemokine Ligand 6(CXCL6) in Models of Early Alcoholic Liver Disease

Overview
Journal Bioengineered
Date 2022 Feb 14
PMID 35156518
Authors
Affiliations
Soon will be listed here.
Abstract

Alcoholic liver disease (ALD) denotes a series of liver diseases caused by ethanol. Recently, immune-related genes (IRGs) play increasingly crucial role in diseases. However, it's unclear the role of IRGs in ALD. Bioinformatic analysis was used to discern the core immune-related differential genes (IRDGs) in the present study. Subsequently, Cell Counting Kit-8 say, oil red O staining, and triglyceride detection were employed to explore optimal experimental conditions of establishing hepatocellular models of early ALD. Ultimately, real-time reverse transcription-PCR and immunohistochemistry/immunocytochemistry methods were adopted to verify the expressions of mRNA and proteins of core IRDGs, respectively. C-X-C Motif Chemokine Ligand 1 () and were regarded as core IRDGs via integrated bioinformatics analysis. Besides, Lieber Decarli Ethanol feeding and 200 mM and 300 mM ethanol stimulating L02 cells for 36 h can both successfully hepatocellular model. In ethanol groups, the levels of CXCL1 and CXCL6 mRNA were significantly upregulated than pair-fed groups (P < 0.0001). Also, immunohistochemistry revealed that positive particles of CXCL1 and CXCL6 in mice model of early ALD were obviously more than control groups (P < 0.0001). Besides, in L02 hepatocytes stimulated by ethanol, CXCL1 and CXCL6 mRNA were over-expressed, compared with normal L02 cells (P < 0.0001). Meanwhile, immunocytochemistry indicated that CXCL1 and CXCL6 proteins in hepatocellular model of early ALD were higher than normal L02 hepatocytes stimulus (P < 0.0001). Ethanol promoted the upregulation of and mRNA and proteins in models of early ALD, denoting their potentiality of acting as biomarkers of ALD.

Citing Articles

Intestinal microbiota homeostasis analysis in riboflavin-treated alcoholic liver disease.

Shen X, Shi C, Xu J, Zhi F, Luo K, Di Y Commun Biol. 2024; 7(1):1030.

PMID: 39169207 PMC: 11339332. DOI: 10.1038/s42003-024-06722-4.


The Clinical Significance and Role of CXCL1 Chemokine in Gastrointestinal Cancers.

Korbecki J, Bosiacki M, Barczak K, Lagocka R, Chlubek D, Baranowska-Bosiacka I Cells. 2023; 12(10).

PMID: 37408240 PMC: 10217339. DOI: 10.3390/cells12101406.


The role of CXCL family members in different diseases.

Zhou C, Gao Y, Ding P, Wu T, Ji G Cell Death Discov. 2023; 9(1):212.

PMID: 37393391 PMC: 10314943. DOI: 10.1038/s41420-023-01524-9.


Myeloid cells in alcoholic liver diseases: Mechanism and prospect.

Xu W, Wu M, Chen B, Wang H Front Immunol. 2022; 13:971346.

PMID: 36032154 PMC: 9399804. DOI: 10.3389/fimmu.2022.971346.

References
1.
Jiang A, Ren M, Liu N, Gao H, Wang J, Zheng X . Tumor Mutation Burden, Immune Cell Infiltration, and Construction of Immune-Related Genes Prognostic Model in Head and Neck Cancer. Int J Med Sci. 2021; 18(1):226-238. PMC: 7738958. DOI: 10.7150/ijms.51064. View

2.
Zeng C, Xing W, Liu Y . Identification of UGP2 as a progression marker that promotes cell growth and motility in human glioma. J Cell Biochem. 2019; 120(8):12489-12499. DOI: 10.1002/jcb.28515. View

3.
Zheng L, Lv G, Sheng J, Yang Y . Effect of miRNA-10b in regulating cellular steatosis level by targeting PPAR-alpha expression, a novel mechanism for the pathogenesis of NAFLD. J Gastroenterol Hepatol. 2009; 25(1):156-63. DOI: 10.1111/j.1440-1746.2009.05949.x. View

4.
Grissa D, Rasmussen D, Krag A, Brunak S, Jensen L . Alcoholic liver disease: A registry view on comorbidities and disease prediction. PLoS Comput Biol. 2020; 16(9):e1008244. PMC: 7531835. DOI: 10.1371/journal.pcbi.1008244. View

5.
Gao X, Wang X, Zhang S . Bioinformatics identification of crucial genes and pathways associated with hepatocellular carcinoma. Biosci Rep. 2018; 38(6). PMC: 6239270. DOI: 10.1042/BSR20181441. View